18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial

Rathan M. Subramaniam, Fenghai M. Duan, Justin Romanoff, Jian Qin Yu, Twyla Bartel, Farrokh Dehdashti, Charles M. Intenzo, Lilja Solnes, Jo Rean Sicks, Brendan C. Stack, Val J. Lowe

Research output: Contribution to journalArticlepeer-review

Abstract

To our knowledge, no prior multicenter clinical trial has reported interobserver agreement of 18F-FDG PET/CT scans for staging of clinical N0 neck in head and neck cancer. Methods: A total of 287 participants were recruited. For visual analysis, positive nodal uptake of 18F-FDG was defined as uptake visually greater than activity seen in the blood pool. Results: The negative predictive value of the 18F-FDG PET/CT for N0 clinical neck was 86% or above for visual assessment (95% CI, 86%-88%) for the 2 central readers and above 90% (95% CI, 90%-95%) for SUVmax for central reads and site reads dichotomized at the optimal cutoff value of 1.8 and the prespecified cutoff value of 3.5, respectively. The κ coefficients between the 2 expert readers and between central reads and site reads varied between 0.53 and 0.78. Conclusion: The NPV of the 18F-FDG PET/CT for N0 clinical neck was 86% or above for visual assessment and above 90% for SUVmax cut points of 1.8 and 3.5 with moderate to substantial agreements.

Original languageEnglish (US)
Pages (from-to)1887-1890
Number of pages4
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume63
Issue number12
DOIs
StatePublished - Dec 1 2022

Keywords

  • FDG PET/CT
  • head and neck cancer
  • oncology: head and neck
  • staging

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of '18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial'. Together they form a unique fingerprint.

Cite this